- Conditions
- Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Interventions
- Pembrolizumab, Stereotactic Body Radiation Therapy
- Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 254
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
Location Directory
Clinical trials in Durham, North Carolina
This page shows live ClinicalTrials.gov search results for Durham, North Carolina, with direct links to official study records plus on-page filtering and sorting for broad location searches.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1193
Shown on this page
12
Current sort
Recently updated
Location scope
Durham, NC
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 205–216 of 1,193 matching trials in Durham, NC.
Live ClinicalTrials.gov results.
Institutions in Durham
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Rupture of Anterior Cruciate Ligament
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 1,234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2030
- U.S. locations
- 47
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 39 more
- Conditions
- Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
- Interventions
- Roflumilast, Azithromycin
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 1,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 23 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Eltrekibart, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Rogers, Arkansas + 34 more
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- Cardiovascular Disease
- Interventions
- Olpasiran, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years to 105 Years
- Enrollment
- 11,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 205
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 170 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Proteinuric Kidney Disease
- Interventions
- Inaxaplin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 67 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • Hollywood, Florida • Lauderdale Lakes, Florida + 28 more
- Conditions
- Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta, Aneurysm Thoracic, Aneurysm Dissecting, Transection Aorta, Intramural Hematoma
- Interventions
- Endovascular
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2038
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 19 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 567
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
- Conditions
- HIV-1-infection
- Interventions
- IAP086 0.3 mcg/kg, IAP086 1 mcg/kg, IAP086 3 mcg/kg, IAP086 6 mcg/kg, IAP086 10 mcg/kg, IAP086 15 mcg/kg, IAP086 25 mcg/kg, IAP086 32 mcg/kg, IAP086 40 mcg/kg
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 594
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more